Kenacort in orabase

PreclinicalProtein / enzyme

HHams Hamed Abdelrahman

Kenacort in orabase is one of 21 small molecule programs targeting Lichen Planus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lichen PlanusActive, not recruiting

Lichen PlanusPreclinical

Active, not recruiting

Competition

Competitive Landscape

29 competitors in Lichen Planus

#DrugCompanyPhaseTrials

Plaquenil

Alnylam Pharmaceuticals

Approved

—2

Decadron

AAspen Global Incorporated

Approved

—3

Elidel

BBausch Health Americas, Inc.

Approved

—4

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Otezla

2 6

Jakafi

Incyte

Phase 2

1 7

Olumiant

Eli Lilly

Phase 2

1 8

Trexall

Alnylam Pharmaceuticals

Phase 2

1 9

Cosentyx

Novartis

Phase 2

1 10

Soriatane

GSK

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lichen Planus1 trial

Glutamine With Topical Corticosteroids for Lichen Planus Treatment

Completed·HHams Hamed Abdelrahman·N/A·NCT04442633·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Kenacort in orabase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Kenacort in orabase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Kenacort in orabase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hams Hamed Abdelrahman company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Preclinical[1]
Company: HHams Hamed Abdelrahman

Kenacort in orabase

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lichen Planus1 trial

References

Drug Info

Quick Facts

Related News